Suchergebnisse - (Subject:"lopinavir")

PubPharm (45)

1

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288) : a prospective strategy study

enthalten in: The lancet. HIV | 2019

von Grinsztejn, B. | Hughes, M. | Ritz, J. | +80

2

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST) : 144-week follow-up results from a randomised controlled trial

enthalten in: The Lancet. Infectious diseases | 2018

von Hakim, J. | Thompson, J. | Kityo, C. | +114

CommentIn: Lancet Infect Dis. 2018 Jan;18(1):3-5. - PMID 29108798

3

Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire : the MONOD ANRS 12206 non-inferiority randomised trial

enthalten in: BMC medicine | 2017

von Dahourou, D. | Amorissani-Folquet, M. | Malateste, K. | +19

4

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen : a substudy of the randomised, open-label, non-inferiority SECOND-LINE study

enthalten in: The lancet. HIV | 2017

von Boyd, M. | Amin, J. | Mallon, P. | +14

CommentIn: Lancet HIV. 2017 Jun;4(6):e240. - PMID 28576610

5

Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa : Analyses From the EARNEST Trial

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2016

von Kambugu, A. | Thompson, J. | Hakim, J. | +10

6

Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060

enthalten in: PloS one | 2016

von Hobbs, C. | Gabriel, E. | Kamthunzi, P. | +20

7

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE) : a randomised, open-label, non-inferiority trial

enthalten in: The Lancet. Infectious diseases | 2015

von Arribas, J. | Girard, P. | Landman, R. | +118

CommentIn: Lancet Infect Dis. 2015 Jul;15(7):748-9. - PMID 26062879

8

Drug susceptibility and resistance mutations after first-line failure in resource limited settings

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2014

von Wallis, C. | Aga, E. | Ribaudo, H. | +7

9

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection : 48 week results of the randomised, open label, non-inferiority GARDEL trial

enthalten in: The Lancet. Infectious diseases | 2014

von Cahn, P. | Andrade-Villanueva, J. | Arribas, J. | +45

CommentIn: Lancet Infect Dis. 2014 Jul;14(7):535-7. - PMID 24783987

10

First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting

enthalten in: AIDS (London, England) | 2014

von Clumeck, N. | Mwamba, C. | Kabeya, K. | +9

1
2
3
4
5
Nächster »
[5]